The results demonstrated that in the LS group, which typically exhibits better chemotherapy outcomes, no patients carrying SDHB/C/D or PDCD1LG2 mutations were observed (Fig. 5A and C). This evidence concerns the gene PDCD1LG2 and Leigh syndrome.